How many restricted share units did the Avanos (AVNS) director receive in this Form 4?

The director received 12,003 restricted share units in this transaction. Each unit represents a contingent right to a cash payment equal to one share of Avanos common stock, replacing a previous grant from January 2, 2025.

Are the Avanos (AVNS) restricted share units granted to the director settled in stock or cash?

The restricted share units are settled in cash rather than stock. Each unit gives a contingent right to receive a cash payment equal to the value of one share of Avanos Medical’s common stock at settlement.

When do the Avanos Medical (AVNS) director’s new restricted share units vest?

The restricted share units vest when the director terminates service on Avanos Medical’s Board of Directors. This means vesting is linked to the end of her board tenure, encouraging longer-term board service alignment.

What prior award did the new Avanos (AVNS) restricted share units replace?

The 12,003 restricted share units issued on May 8, 2026, replaced restricted share units previously granted to the director on January 2, 2025. The filing notes this substitution directly in the transaction footnotes.

Avanos Medical (NYSE: AVNS) director awarded 12,003 cash-settled RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Franchini Indrani Lall reported acquisition or exercise transactions in this Form 4 filing.

Avanos Medical director Indrani Lall Franchini received a grant of 12,003 restricted share units on May 8, 2026. These units are a cash-settled award, each representing a contingent right to receive a payment equal to the value of one share of Avanos common stock.

The new 12,003 restricted share units replace a prior grant originally issued on January 2, 2025. The units vest when Franchini terminates her service on Avanos Medical’s Board of Directors, aligning the award with her continued board tenure rather than short-term performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Franchini Indrani Lall

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	12,003	$0.00	--

Holdings After Transaction: Restricted Share Units — 12,003 shares (Direct, null)

Footnotes (1)

Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025. The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors.

Key Figures

RSU grant size: 12,003 units Exercise price: $0.00 per unit Units after transaction: 12,003 units +3 more

6 metrics

RSU grant size 12,003 units Restricted share units granted May 8, 2026

Exercise price $0.00 per unit Restricted share units grant price

Units after transaction 12,003 units Total restricted share units following grant

Underlying shares 12,003 shares equivalent Each unit equal to one share’s value in cash

Vesting condition Upon board service termination Units vest when director leaves Board of Directors

Original grant replaced January 2, 2025 award New RSUs issued to replace prior RSU grant

Key Terms

Restricted Share Units, contingent right, cash payment equal to the value of one share, vest, +1 more

5 terms

contingent right financial

"Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share"

vest financial

"The restricted share units vest on the date the Reporting Person terminates service"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Board of Directors other

"terminates service on the Issuer's Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

05/12/2026 - 11:40 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Franchini Indrani Lall

(Last)

(First)

(Middle)

5405 WINDWARD PARKWAY

(Street)

ALPHARETTA

GEORGIA

30004

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽¹⁾	05/08/2026		A		12,003		⁽²⁾	⁽²⁾	Common Stock	12,003	$0	12,003	D

Explanation of Responses:

1. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025.

2. The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors.

Remarks:

	/s/ John Fischer, as attorney-in-fact for Indrani Franchini	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Avanos Medical (AVNS) report for Indrani Lall Franchini?

Avanos Medical reported that director Indrani Lall Franchini received 12,003 restricted share units on May 8, 2026. The award is a cash-settled grant tied to the value of Avanos common stock and vests when her board service ends.

Did this Avanos (AVNS) Form 4 involve any open-market stock purchases or sales?

No, the Form 4 reflects a grant of restricted share units as compensation, not open-market trades. There were no reported stock purchases or sales; the award is a derivative, cash-settled incentive tied to share value.